Discontinuing directly acting antivirals during hepatitis C treatment: highlighting an infrequent but hostile event - 24/11/22
Doi : 10.1016/j.clinre.2022.102042
Mohamed El-Kassas a, ⁎ 
, Sherif Elbehiry b, Enas Rezk c, Dalia Omran d, Ahmed Sherief e, Mohamed Eltabbakh e, Inas Moaz f, Adel TEl ahan c, Mohammad Abdalgaber g, Haidy Khalil h, Mohamed Alboraie i, Amr El Fouly a, Mohammed Aboul-Ezz j, Amany Wahb k, Ahmed Madkour a
, Sherif Elbehiry b, Enas Rezk c, Dalia Omran d, Ahmed Sherief e, Mohamed Eltabbakh e, Inas Moaz f, Adel TEl ahan c, Mohammad Abdalgaber g, Haidy Khalil h, Mohamed Alboraie i, Amr El Fouly a, Mohammed Aboul-Ezz j, Amany Wahb k, Ahmed Madkour a a Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo 11795, Egypt
b Internal Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt
c New Cairo Viral Hepatitis Treatment Unit, New Cairo Hospital, Cairo, Egypt
d Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
e Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
f Epidemiology and Preventive Medicine Department, National Liver Institute, Menoufia University, Menoufia, Egypt
g Hepatology and Gastroenterology Department, AGOZA Police Hospital, Cairo, Egypt
h Microbiology and Immunology Department, Faculty of Medicine, Helwan University, Cairo, Egypt
i Internal Medicine Department, Al-Azhar University, Cairo, Egypt
j Hepatology and Gastroenterology Department, Theodor Bilharz Research Institute, Cairo, Egypt
k Medical Biochemistry and Molecular Biology department, Faculty of Medicine, Helwan University, Cairo, Egypt
⁎Corresponding author.
Highlights |
• | Treatment of chronic hepatitis C virus (HCV) with new direct-acting antiviral agents (DAAs) has been proven efficacious and safe in many clinical trials. |
• | Several factors influence patient compliance with DAAs, and cause treatment discontinuation, resulting in waste of money and effort that could exhaust the health care system. |
• | Treatment regimen, longer treatment duration, and unfavorable liver functions were associated with treatment discontinuation. |
Plan
© 2022
Elsevier Masson SAS. Tous droits réservés.
Vol 46 - N° 10
Article 102042- décembre 2022 Retour au numéro
Article précédent
- Drug induced hepatitis and SARS-CoV-2 vaccination: Correspondence
- Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
- Bulevirtide 2mg-based real-life treatment of hepatitis Delta with genotypes 1 and 5 viruses at more than 20 months of follow-up
- Clara Dassetto, Patrick Borentain, René Gérolami, Philippe Colson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?